|
N,N'-bis(4-cyanophenyl)-2-methylpropanediamide |
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Singh VK, et al. 2022. Nat Commun |
|
N,N'-bis(4-cyanophenyl)propanediamide |
Depiction based on curated SMILES
O
N
NH
N
O
N
H
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Singh VK, et al. 2022. Nat Commun |
|
N-(4-cyanophenyl)-N'-(6-cyanopyridin-3-yl)propanediamide |
Depiction based on curated SMILES
O
N
N
NH
N
O
N
H
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Singh VK, et al. 2022. Nat Commun |
|
N-phenyl-2-{[4-(thiophen-2-yl)pyrimidin-2-yl]sulfanyl}acetamide |
Depiction based on curated SMILES
NH
N
S
O
N
S
|
Pseudomonas |
Biofilm |
Preclinical (in vitro) |
Starkey M, et al. 2014. PLoS Pathog |
|
5-chloro-N-(3-chloro-4-methoxyphenyl)-2-(methylsulfonyl)pyrimidine-4-carboxamide |
Depiction based on curated SMILES
O
O
CH
3
S
Cl
N
N
O
N
H
Cl
CH
3
O
|
Shigella |
VirF |
Preclinical (in vitro) |
Emanuele AA, et al. 2014. J Antibiot (Tokyo); Emanuele AA, et al. 2015. PLoS One |
|
N-[2-(2-aminopyrimidin-5-yl)phenyl]-3,5-dibromobenzamide |
Depiction based on curated SMILES
N
Br
Br
NH
2
O
NH
N
|
Staphylococcus |
Biofilm |
Preclinical (in vitro) |
Weig AW, et al. 2021. RSC Med Chem |
|
N-[3-(2-aminopyrimidin-4-yl)phenyl]-3,5-dibromobenzamide |
Depiction based on curated SMILES
N
Br
Br
H
2
N
O
N
H
N
|
Staphylococcus |
Biofilm |
Preclinical (in vitro) |
Weig AW, et al. 2021. RSC Med Chem |
|
N-[3-(2-aminopyrimidin-4-yl)phenyl]-3,5-dichlorobenzamide |
Depiction based on curated SMILES
N
Cl
Cl
H
2
N
O
N
H
N
|
Staphylococcus |
Biofilm |
Preclinical (in vitro) |
Weig AW, et al. 2021. RSC Med Chem |
|
N-[3-(2-aminopyrimidin-4-yl)phenyl]-3-bromo-5-chlorobenzamide |
Depiction based on curated SMILES
N
Cl
Br
O
NH
2
HN
N
|
Staphylococcus |
Biofilm |
Preclinical (in vitro) |
Weig AW, et al. 2021. RSC Med Chem |
|
N-[3-(2-aminopyrimidin-5-yl)phenyl]-3,5-dibromobenzamide |
Depiction based on curated SMILES
N
Br
Br
NH
2
O
N
H
N
|
Staphylococcus |
Biofilm |
Preclinical (in vitro) |
Weig AW, et al. 2021. RSC Med Chem |
|
| | |